Gilead Sciences (NASDAQ:GILD)
This week we learned that the letter sent by Congressman Waxman to Gilead may have been political gamesmanship. We spoke with GILD company representatives and their story was very interesting because it casts the recent biotech selloff in a completely new light. If you read this story when we originally published it last Monday - read it again to catch the story updates since then.
Mannkind Corporation (NASDAQ:MNKD)
Mannkind received a highly positive vote from the panel in it's Advisory Committee meeting. Read the article to find out what's next for the company and for the Afrezza approval process.
Pfizer (NYSE:PFE)
Pfizer reported highly-anticipated data from the PALOMA-1 study of Palbociclib in ER+/HER2- breast cancer at AACR. Palbociclib nearly doubled progression free survival compared to standard of care. Read the article for details including where buy side expectations were ahead of the data.